General considerations on rapid desensitization for drug hypersensitivity - a consensus statement.
about
What we know about nonsteroidal anti-inflammatory drug hypersensitivityImmediate-type hypersensitivity drug reactionsDrug allergy: causes and desensitizationDesensitization to Oxcarbazepine: Long-Term Efficacy and TolerabilityRisk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization StatementA retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergyClinical applications of drug desensitization in the Asia-Pacific region.Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivityKnowledge, attitudes, and practices survey of drug allergy among healthcare practitioners in central China: a multicenter study.In vitro desensitization of human skin mast cells.An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusionsRituximab Desensitization in Pediatric Patients: Results of a Case SeriesRapid desensitization induces internalization of antigen-specific IgE on mouse mast cells.Mast cell desensitization inhibits calcium flux and aberrantly remodels actin.Successful Desensitisation in a Patient with CRIM-Positive Infantile-Onset Pompe Disease.Desensitization to antibiotics in children.Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group.Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes.Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations.Medication Desensitization: Characterization of Outcomes and Risk Factors for Reactions.AllergoOncology - the impact of allergy in oncology: EAACI position paper.Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics.Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity.Optimal step doses for drug provocation tests to prove beta-lactam hypersensitivity.Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization.Hypersensitivity reaction and tolerance induction to ethambutolClinical allergy. Managing generalized interferon-induced eruptions and the effectiveness of desensitization.High incidence of skin rash in patients with hairy cell leukemia treated with cladribine.Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations.Rapid desensitization to chemotherapy and monoclonal antibodies is effective and safe.Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment.Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper.Recovery from desensitization of IgE-dependent responses in human lung mast cells.A successful desensitization protocol for horse-derived antithymocyte globulin in severe aplastic anemia.Management of allergy to penicillins and other beta-lactams.Intentional rechallenge: does the benefit outweigh the risk?Methotrexate hypersensitivity reactions in pediatrics: Evaluation and management.An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity.
P2860
Q26749250-1D1E0306-13A4-4866-9D5E-536CB5B6DB7BQ26995860-99A54C94-4084-43E4-9C47-299C3FC68949Q27012238-3F51CB3C-1914-4368-A351-4956CEF6ED13Q28468283-425FFBD0-E04D-409E-BB61-8CE280429EE1Q30371972-C30254DB-D09D-4327-B528-12FA45E3071EQ33974514-40D5F8CC-7770-4977-9B53-BEFD0019352CQ35502326-71042568-09D9-4F5C-9FB4-5675918F2D13Q35657599-1C29B28D-68BE-40BC-8756-8C020F661B70Q36370958-5BE884DD-A878-492A-8173-520B11878F5EQ36850154-9E37052D-52B1-4A00-86DB-FB96E7335B24Q36934433-4E2C7A84-BC97-4B5C-A8A3-BA3B36239621Q37012130-9ED1C6B7-FCCB-4B95-B5FB-3D427668856BQ37050013-C533ACCF-A9E9-4FE2-930B-6003DD276F0EQ37213198-B7FAD5AD-AA0B-4454-B33E-A8739FE7EBE9Q37395868-E34578D1-2A80-4BEC-8D37-603C42DE6C4EQ37500689-EE92B1E8-B18E-49AD-A908-374EECFE2491Q38042076-FAAB266B-CA1A-488B-B1E0-0B0190555662Q38112758-BC70F083-CAD7-4943-88C0-FBB227EADC9FQ38226223-3C486621-3181-4BD0-B96E-BD8528F7DDC2Q38233315-629AEA9E-24AA-4890-BD22-154031A62E15Q38702429-BD5D8512-2734-4814-9F8E-23178BB93E43Q38776716-9B65B861-CC18-4D1D-8834-25CCE2CA751BQ38859163-6B9F18AA-DAA4-44F9-AF77-79A152B04ACAQ39042503-15187C66-2E4B-4E74-B040-CCEF1E187552Q39299067-7BE4FD4A-339F-49F9-8DFA-AB9F36A7AC4EQ39446009-8FC9CCDF-B8FF-4DAD-A53D-30A49B9BF085Q41127404-4C067818-2FC2-46D2-8A5F-B1C0E11CCD17Q41963667-7B1B0C47-2852-4110-ABE4-9441DE028A8FQ42262329-A917ED92-D8C3-4CBE-872F-11984CC0E1BAQ43614460-970AEC9D-F151-4BE9-95F8-7FFFCED33223Q44842257-16EE38D3-E420-4169-93D3-6061F03DC77AQ45090509-E4BCA3B5-7E87-4CA5-82DF-A0E479063239Q46287048-4E6FA7F9-DE30-4D46-9A31-351A91658A93Q46912843-88EF6C22-BD57-4343-BA54-095D89E1F091Q47965255-2006760D-DA0E-4767-B3A6-DCFA04AE0270Q50592119-C7DC9C7B-36F8-4875-95B2-4164D402B854Q50969804-4D1CD990-5951-4BC0-BA30-D5EACF0AC596Q51253226-C1DEBF2D-E2F3-4235-80D8-8EEF3C463D0FQ54839689-31DC271B-BE22-474F-A23D-C7B15399554AQ55344908-EE36AEC8-B485-4224-A791-E06687A36C06
P2860
General considerations on rapid desensitization for drug hypersensitivity - a consensus statement.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
General considerations on rapi ...... ivity - a consensus statement.
@en
General considerations on rapi ...... ivity - a consensus statement.
@nl
type
label
General considerations on rapi ...... ivity - a consensus statement.
@en
General considerations on rapi ...... ivity - a consensus statement.
@nl
prefLabel
General considerations on rapi ...... ivity - a consensus statement.
@en
General considerations on rapi ...... ivity - a consensus statement.
@nl
P2093
P2860
P50
P1433
P1476
General considerations on rapi ...... tivity - a consensus statement
@en
P2093
European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity
J R Cernadas
M Castells
P2860
P304
P356
10.1111/J.1398-9995.2010.02441.X
P577
2010-08-17T00:00:00Z